Oslo 01.07.2013 – The study was recently presented by Prof. Lars Østergaard from Aarhus University Hospital at Bionor Pharma’s Capital Markets Day in Oslo, 14 June. See article in the Danish newspaper Berlingske 30 June about the research with HDAC Inhibitors in HIV patients, presented at the conference in Kuala Lumpur: http://www.b.dk/nationalt/dansk-gennembrud-i-kampen-mod-hiv# See also information at …
Oslo 13.06.2013 – The highest dose of lenalidomide has been chosen for the second, placebo-controlled part of the study, where a number of HIV patients are ready for screening Bionor Pharma ASA (OSE: BIONOR) announced today that the first part of its phase II clinical study combining the HIV vaccine, Vacc-4x, with Celgene’s immunomodulator, lenalidomide, …
Oslo, 11.06.2013 – Bionor Pharma ASA (OSE: BIONOR) announced today that it has filed an International Patent Application for its HIV Vaccine, Vacc-HIV. This application gives Bionor Pharma the opportunity to obtain patent protection for Vacc-HIV in all the major international pharmaceutical markets. Vacc-HIV, which is currently in the preclinical stage of development, is a …
